T 25 (Tarceva 25 mg)
Generic Name: erlotinib
Pill imprint T 25 has been identified as Tarceva 25 mg.
Tarceva is used in the treatment of non-small cell lung cancer; pancreatic cancer; renal cell carcinoma and belongs to the drug class EGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Tarceva 25 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- T 25
- 25 mg
- Prescription only
- Drug Class:
- EGFR inhibitors
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- National Drug Code (NDC):
|NDC Code||Manufacturer / Repackager|
|54868-5290||Physicians Total Care Inc (repackager)|
Note: Inactive ingredients may vary.
More about Tarceva (erlotinib)
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.